<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00687388</url>
  </required_header>
  <id_info>
    <org_study_id>2006-07-084</org_study_id>
    <nct_id>NCT00687388</nct_id>
  </id_info>
  <brief_title>The Clinical Efficacy of Non-steroidal Anti-inflammation Drugs in Patients With Benign Prostatic Hyperplasia</brief_title>
  <official_title>The Clinical Efficacy of Non-steroidal Anti-inflammation Drugs in Patients With Benign Prostatic Hyperplasia: A Prospective Randomized Multicenter Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Korean Urological Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Non-steroidal Anti-inflammation Drugs can effectively reduce the lower urinary tract symptoms
      from benign prostatic hyperplasia
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    in order to prepare a new clinical trial to evaluate with pathological change
  </why_stopped>
  <start_date>May 2008</start_date>
  <primary_completion_date type="Anticipated">March 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The changes of International Prostatic Symptom Scores after medications</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The changes of voiding frequencies after medications</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The changes of 'ICS male questionnaire-short form' after medications</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient perception of treatment benefit questionnaire</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The changes of 'patient perception of bladder condition' after medications</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The changes of maximum flow rate and postvoid residuals after medications</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The changes of serum PSA levels after medications</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The changes of WBC counts on the expressed prostatic secretions after medications</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications</measure>
    <time_frame>During all study periods</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Benign Prostatic Hyperplasia</condition>
  <arm_group>
    <arm_group_label>Alpha-blocker</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Alpha-blocker only</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NSAID</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>NSAID only</description>
  </arm_group>
  <arm_group>
    <arm_group_label>alpha-blocker and NSAID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination treatment of alpha-blocker and NSAID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>selective alpha 1-blockers</intervention_name>
    <description>Continued medication that the patient had before the enrollment of this study (tamsulosin 0.2mg, alfuzosin 10mg, doxazosin 4, 8mg, or terazosin 2-10mg daily for 8 weeks)</description>
    <arm_group_label>Alpha-blocker</arm_group_label>
    <other_name>tamsulosin</other_name>
    <other_name>alfuzosin</other_name>
    <other_name>doxazosin</other_name>
    <other_name>terazosin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>celecoxib</intervention_name>
    <description>200mg daily for 8 weeks</description>
    <arm_group_label>NSAID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>alpha-blocker and NSAID</intervention_name>
    <description>amsulosin 0.2mg, alfuzosin 10mg, doxazosin 4, 8mg, or terazosin 2-10mg daily for 8 weeks and celecoxib 200mg daily for 8 weeks</description>
    <arm_group_label>alpha-blocker and NSAID</arm_group_label>
    <other_name>tamsulosin and celecoxib</other_name>
    <other_name>alfuzosin and celecoxib</other_name>
    <other_name>doxazosin and celecoxib</other_name>
    <other_name>terazosin and celecoxib</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Who had the treatment of BPH with alpha-1 blockers for more than 3 months

          -  Who have the IPSS(International Prostatic Symptom Score) &gt;= 15

          -  Who have the maximum flow rate(Qmax) &lt; 15 with voided volume &gt; 150mL

          -  Who have the PPBC(patient's perception of bladder condition) &gt;= 3 (The PPBC was
             assessed by the use of a six point ordered categorical scale(1-6 point). The higher
             score means the higher bother)

          -  Who had the PSA level &lt; 4 ng/mL within 6 months (But, the patient who are revealed not
             to have prostate cancer by prostate biopsy can be included even if he had PSA level of
             4-10 ng/mL)

          -  Who underwent the transrectal ultrasound of prostate within 6 months

          -  Who can understand this study and can give the informed consent

        Exclusion Criteria:

          -  Who had regular intake of 5-alpha reductase inhibitor or NSAID within 6 months before
             screening

          -  Who have peptic ulcer and/or asthma

          -  Who have urologic malignancies such as prostate cancer and bladder cancer

          -  Who have urethral strictures, large bladder diverticuli, and bladder neck contractures

          -  Who had surgical treatment for BPH

          -  Who have histories of bladder and/or urethra

          -  Who have serum PSA level more than 10 ng/ml

          -  Who have histories of orthostatic hypotension

          -  Who have serum creatinine level more than 2.0 mg/dl

          -  Who have serum ALT and/or AST level more than 1.5 times of normal upper limit

          -  Who have heart failure

          -  Who have histories of bacterial prostatitis within 1 year

          -  Who have histories of active urinary tract infection within 1 month

          -  Who have histories of the biopsy of bladder and prostate within 1 month

          -  Who are unable to void

          -  Who use pads because of incontinences

          -  Who have hypersensitivities for alpha blockers that include quinazoline, NSAID,
             aspirin, sulfonamide

          -  Who have histories of unstable angina, myocardial infarction, and cerebrovascular
             accident within 6 months

          -  Who have neurogenic bladder due to multiple sclerosis, Parkinson's disease, Spinal
             injuries and etc.

          -  Who have thinking disturbances

          -  Who have histories of abuses of alcohol and/or other drugs

          -  Who seem to be not fit to this study by the decision of investigators
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyu-Sung Lee, Ph.D., M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Kramer G, Steiner GE, Handisurya A, Stix U, Haitel A, Knerer B, Gessl A, Lee C, Marberger M. Increased expression of lymphocyte-derived cytokines in benign hyperplastic prostate tissue, identification of the producing cell types, and effect of differentially expressed cytokines on stromal cell proliferation. Prostate. 2002 Jun 1;52(1):43-58.</citation>
    <PMID>11992619</PMID>
  </reference>
  <reference>
    <citation>Untergasser G, Madersbacher S, Berger P. Benign prostatic hyperplasia: age-related tissue-remodeling. Exp Gerontol. 2005 Mar;40(3):121-8. Epub 2005 Jan 22. Review.</citation>
    <PMID>15763388</PMID>
  </reference>
  <reference>
    <citation>Lee KL, Peehl DM. Molecular and cellular pathogenesis of benign prostatic hyperplasia. J Urol. 2004 Nov;172(5 Pt 1):1784-91. Review.</citation>
    <PMID>15540721</PMID>
  </reference>
  <reference>
    <citation>Handisurya A, Steiner GE, Stix U, Ecker RC, Pfaffeneder-Mantai S, Langer D, Kramer G, Memaran-Dadgar N, Marberger M. Differential expression of interleukin-15, a pro-inflammatory cytokine and T-cell growth factor, and its receptor in human prostate. Prostate. 2001 Dec 1;49(4):251-62.</citation>
    <PMID>11746271</PMID>
  </reference>
  <reference>
    <citation>Kakehi Y, Segawa T, Wu XX, Kulkarni P, Dhir R, Getzenberg RH. Down-regulation of macrophage inhibitory cytokine-1/prostate derived factor in benign prostatic hyperplasia. Prostate. 2004 Jun 1;59(4):351-6.</citation>
    <PMID>15065082</PMID>
  </reference>
  <reference>
    <citation>Steiner GE, Newman ME, Paikl D, Stix U, Memaran-Dagda N, Lee C, Marberger MJ. Expression and function of pro-inflammatory interleukin IL-17 and IL-17 receptor in normal, benign hyperplastic, and malignant prostate. Prostate. 2003 Aug 1;56(3):171-82.</citation>
    <PMID>12772186</PMID>
  </reference>
  <reference>
    <citation>Wang W, Bergh A, Damber JE. Chronic inflammation in benign prostate hyperplasia is associated with focal upregulation of cyclooxygenase-2, Bcl-2, and cell proliferation in the glandular epithelium. Prostate. 2004 Sep 15;61(1):60-72.</citation>
    <PMID>15287094</PMID>
  </reference>
  <reference>
    <citation>Kramer G, Marberger M. Could inflammation be a key component in the progression of benign prostatic hyperplasia? Curr Opin Urol. 2006 Jan;16(1):25-9. Review.</citation>
    <PMID>16385197</PMID>
  </reference>
  <reference>
    <citation>Rohrmann S, De Marzo AM, Smit E, Giovannucci E, Platz EA. Serum C-reactive protein concentration and lower urinary tract symptoms in older men in the Third National Health and Nutrition Examination Survey (NHANES III). Prostate. 2005 Jan 1;62(1):27-33.</citation>
    <PMID>15389816</PMID>
  </reference>
  <reference>
    <citation>Araki T, Yokoyama T, Kumon H. Effectiveness of a nonsteroidal anti-inflammatory drug for nocturia on patients with benign prostatic hyperplasia: a prospective non-randomized study of loxoprofen sodium 60 mg once daily before sleeping. Acta Med Okayama. 2004 Feb;58(1):45-9.</citation>
    <PMID>15157011</PMID>
  </reference>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 27, 2008</study_first_submitted>
  <study_first_submitted_qc>May 29, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 30, 2008</study_first_posted>
  <last_update_submitted>June 7, 2013</last_update_submitted>
  <last_update_submitted_qc>June 7, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 10, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>KYU-SUNG LEE</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Cyclooxygenase 2 Inhibitors</keyword>
  <keyword>Alpha Blockers</keyword>
  <keyword>Treatment Outcome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
    <mesh_term>Prostatic Hyperplasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celecoxib</mesh_term>
    <mesh_term>Anti-Inflammatory Agents, Non-Steroidal</mesh_term>
    <mesh_term>Tamsulosin</mesh_term>
    <mesh_term>Doxazosin</mesh_term>
    <mesh_term>Alfuzosin</mesh_term>
    <mesh_term>Terazosin</mesh_term>
    <mesh_term>Prazosin</mesh_term>
    <mesh_term>Adrenergic alpha-Antagonists</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

